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As ﬁne regulators of gene expression, non-coding RNAs, andmore particularly micro-RNAs
(miRNAs), have emerged as key players in the development of the nervous system. In
vivo experiments manipulating miRNAs expression as neurogenesis proceeds are very
challenging in the mammalian embryo and totally impossible in the human. Human
pluripotent stem cells (hPSCs), from embryonic origin (hESCs) or induced from adult
somatic cells (iPSCs), represent an opportunity to study the role of miRNAs in the earliest
steps of human neurogenesis in both physiological and pathological contexts. Robust
protocols are now available to convert pluripotent stem cells into several sub-types of
fully functional neurons, recapitulating key developmental milestones along differentiation.
This provides a convenient cellular system for dissecting the role of miRNAs in phenotypic
transitions critical to brain development and plasticity that may be impaired in neurological
diseases with onset during development.The aim of this review is to illustrate how hPSCs
can be used to recapitulate early steps of human neurogenesis and summarize recent
reports of their contribution to the study of the role of miRNA in regulating development
of the nervous system.
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INTRODUCTION
Human neurogenesis is the result of a tightly controlled sequence
of events that associates environmental signals and intra-cellular
molecular mechanisms. Impaired neurogenesis is at the origin
of the so-called neuro-developmental disorders, such as autism
spectrum disorders (ASDs) or Down’s syndrome, and is thought
to be involved in the etiology of psychiatric disorders such as
schizophrenia or bipolar disorders (Moreno-De-Luca et al., 2013).
Micro-RNAs (miRNAs) are abundant, short-lived, double strand
non-coding RNAs (nc-RNAs) of 22 nucleotides that act as post-
transcriptional repressors targeting multiple mRNAs (Yates et al.,
2013). They account for an additional level of intricacy to gene
regulation and, therefore, represent attractive candidates to inter-
pret subtle developmental regulations. Genetic manipulation of
the miRNAs machinery in rodent models severely impaired sev-
eral aspect of neurogenesis (Sun et al., 2013). However, to evaluate
whether this may be relevant to human neurogenesis, both physi-
ologically and in a pathological context, these experiments need to
be replicated and supplemented in humanmodels of neurogenesis.
Over the last decade, human pluripotent stem cells (hPSCs)
have emerged as powerful tools with the potential to further
illuminate key mechanisms underlying neuronal development
(Chamberlain et al., 2008; Crook andKobayashi, 2008). These cells
allow investigators to more speciﬁcally assess aspects of human
neurogenesis that were previously hardly attainable due to tech-
nical obstacles at accessing human embryonic and fetal tissues.
Pluripotent stem cell (PSC) can be obtained from the embryo
inner cell mass or reprogramed from any adult somatic cells
(Gokhale and Andrews, 2012). Their self-renewal property offers
the opportunity to amplify themuntil reaching the cellmass neces-
sary to perform large throughput studies including miRNA whole
genome proﬁling. As PSCs, they can virtually give rise in vitro to
any cell type of the human body including neurons. Of interest,
the differentiation paradigms of hPSC into different sub-types of
neurons recapitulates the key milestones of human neurogenesis
including: (i) early neural commitment and neuro-epithelial cells
differentiation, (ii) regionalization of the early neuro-epithelial
cells into more specialized neural progenitors, (iii) terminal dif-
ferentiation of the specialized progenitors into speciﬁc sub-types
of neurons and maturation of these neurons until the formation
of functional synapses and complex networks. The involvement of
miRNAs in each milestone can therefore be assessed functionally
using genetic manipulation to achieve loss or gain of function into
the cells.
While human embryonic stem cells (hESCs) remain the gold
standard to study the physiological aspects of early human devel-
opment, PSCs reprogramed from adult somatic cells (iPSC) offer
the opportunity to address important issues regarding miRNA
participation to disease etiology in a patient-related genetic back-
ground. Here, we summarize the different steps of human
neurogenesis that can be recapitulated from hPSC and the current
protocols that have been implemented to obtain them. We will
next review the current knowledge regarding miRNA-dependent
regulation in PSC-derived models of neurogenesis. Finally, we
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will discuss the current success of iPSC derivation from patient
with neuro-developmental or early onset psychiatric disorders
and how these new cellular models could help increasing our
understanding about the involvement of miRNAs in human
diseases.
PLURIPOTENT STEM CELLS AS A CELLULAR SYSTEM TO
RECAPITULATE KEY STEPS OF EARLY HUMAN
NEUROGENESIS
ENGAGEMENT OF PLURIPOTENT STEM CELLS INTO THE NEURAL
LINEAGE
The earlier event of human neurogenesis that can be modeled
in vitro using PSC is the conversion of PSCs into the neural lin-
eage to form the ﬁrst population of neural progenitors found in the
neural plate, the neuro-epithelial cells. hPSC may be coaxed along
the neural lineage and differentiate into a population of bipolar
neuro-epithelial cells that express the main markers of the neu-
ral tube, Sox1 and Sox2, and organize in rosette-like multicellular
structures using different methods. One efﬁcient and convenient
protocol was revealed in parallel by Chambers et al. (2009) and our
group (Boissart et al., 2012). PSC are ﬁrst cultivated as amonolayer
then the medium changed to a neural induction medium contain-
ing a combination of inhibitors of both the bone morphogenetic
proteins (BMPs) and transforming growth factor-beta (TGF-β),
Smad-dependent, pathways. After 10–15 days, the neural conver-
sion of PSC into Pax6/Sox1 positive neuro-epithelial cells is fully
achieved.Whenused to inhibit TGF-β-mediated pluripotency net-
works, the smallmolecule SB431542promotes exit of cells fromthe
pluripotent compartment and suppresses mesendodermal fates by
inhibiting endogenous activin and nodal signals. Neural conver-
sion of the resulting ectodermal cells was achieved with addition
of the BMP inhibitorNoggin (Chambers et al., 2009; Boissart et al.,
2012). The resulting neuro-epithelial cells are competent to form
neural “rosettes” that morphologically mimic the neural tube cells
and could further be differentiated into different sub-types of
functional neurons. Clear advantage of this system is its dramatic
efﬁciency and relative simplicity. The efﬁciency of the phenotypic
transition between pluripotency and neural commitment can be
easilymonitored in real-time following themorphological changes
characteristic of the formation of the neuro-epithelium, the so-
called neural “rosettes.”Quantiﬁcation can be achieved measuring
the number of cells expressing the canonical neural markers Sox1
and Pax6 but down-regulating the pluripotency markers Oct-4
and Nanog. This allows the differential large-scale proﬁling of
miRNA expression since both pluripotent and neuro-epithelial
cells can be obtain to near-purity. Finally, the monolayer culture
mode is perfectly adapted to transfection methods and func-
tional validation can easily be conducted (Boissart et al., 2012).
Neural commitment can also be achieved using embryoid bodies
(EBs) where PSCs are differentiated in vitro by spontaneously self-
assembling in suspension into 3D cell aggregates. This technique
of differentiation promotes the formation of the three embryonic
germ layers in parallel. It can be more challenging to manipu-
late these 3D structures than cells differentiated as monolayer;
however, the contribution of a given miRNA to inﬂuence the
balance between the different embryonic fates can be addressed
(Xu et al., 2009).
REGIONAL PATTERNING OF NEURO-EPITHELIAL CELLS
In addition to the acquisition of an early neural fate, neuro-
epithelial cells will progressively adopt a speciﬁc regional identity
along the neural tube axes in response to exogenous factors. The
resulting cells have a more restricted potential and produce only
speciﬁc sub-types of neurons according to their position along
the rostro-caudal and dorso-ventral (DV) axis. Fundamental to
the existence of divergent structures in the brain is the early
region-speciﬁc molecular programing. In mammal embryos, the
anterio-posterior (AP) axis is speciﬁed as neural commitment pro-
ceeds. The closing neural tube quickly divides into three primary
vesicles: the anterior forebrain, the midbrain, and the posterior
hindbrain. The forebrain will further sub-divide into two struc-
tures, the rostral telencephalon and the diencephalon (Pombero
and Martinez, 2009), whereas the caudal hindbrain will form
the rhombencephalon and the spinal cord. Secondary patterning
sequences will further specify DV domains inside each structure
(Lupo et al., 2006). The organization of these secondary vesicles
preﬁgures the future brain structures. The telencephalon will give
rise to the cortex in its dorsal part and to basal ganglia in its ven-
tral part. The thalamus and hypothalamus will emerge from the
ventral diencephalon, the substantia nigra from the ventral mes-
encephalon, the cerebellum from the rhombencephalon, spinal
motor neurons will form from the ventral part of the spinal cord
whereas sensorial neurons will differentiate from the dorsal part
(de Graaf-Peters and Hadders-Algra, 2006).
In vitro regionalization of PSC-derived neuro-epithelial cells
has been achieved successfully for some representative neuronal
populations by translating knowledge from embryogenesis. Dur-
ing embryogenesis, regional patterning is under the control of
extra-cellular signals that provide a group of neural progenitors
with the unique competency to produce speciﬁc neuronal sub-
types. The activity of these signals is spatiotemporally integrated
by neural progenitors to determine the speciﬁc combinations of
transcription factors activated in distinct AP and DV compart-
ments of the central nervous system (CNS; Vieira et al., 2010).
Master factors include Wnt, sonic hedgehog (SHH), ﬁbroblast
growth factors (FGFs), BMPs, and retinoic acid (RA) acting in gra-
dient of concentrations. Anterior fates have been obtained from
PSC using default protocols, in the absence of any morphogen
(Li et al., 2009; Zeng et al., 2010). However, the efﬁciency can be
greatly improved by using inhibitors of the Wnt pathway. The
resulting population of neural progenitors expresses high levels of
the anterior marker FoxG1 and can be further patterned dorsally
or ventrally using the interplay between Wnt and SHH pathways.
Further differentiation of primitive neuro-epithelial cells in the
absence of SHH spontaneously produce neural progenitors that
express the dorsal markers Pax6 and Emx1 and will ultimately
give rise to glutamatergic projection neurons of the different cor-
tical layers (Shi et al., 2012). In contrast, gradual activation of
SHH-dependent pathway allows the successful production of pro-
genitors from the ventral ganglionic eminence, expressing the
markers Nkx2.1 or Gsh-2, and the corresponding cortical or stri-
atal GABAergic interneurons (Carri et al., 2013; Maroof et al.,
2013).
Interplays between RA, FGF-8, and Wnt pathways promote
more caudal fates. Midbrain dopaminergic (mDA) neurons of
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the substantia nigra and the ventral tegmental area emerge from
progenitors located in the ﬂoor plate of the ventral part of the
embryonic midbrain (Ono et al., 2007). Accordingly, most proto-
cols that aim at deriving DA neurons progenitors from hPSC rely
on the exposition of early neuro-epithelial to SHH and to FGF-8, a
weak but sufﬁcient caudalizing factor (Perrier et al., 2004; Anders-
son et al., 2006; Friling et al., 2009; Rhee et al., 2011). Recently, the
smallmoleculeCHIR99021, a glycogen synthase kinase-3 inhibitor
that mimicsWnt pathway activation, has been identiﬁed as a more
potent caudalizing agent than FGF-8, and has been used to pro-
duce high yields of mDA neurons in combination with a modiﬁed
form of SHH (Kirkeby et al., 2011; Kriks et al., 2011). Spinal cord
motorneuronsoriginate from themotoneuronprogenitor domain
located in the ventral developing spinal cord (Soula et al., 2001). In
order to obtain efﬁcient spinal motor neurons in vitro, primitive
neuro-epithelial cells need to be caudalized as the neural induction
proceeds, using high concentrations of RA then ventralized using
SHH (Chipman et al., 2012; Takazawa et al., 2012).
Most of these protocols of directed differentiation are efﬁcient
enough to yield largely enriched population of a given progenitor
sub-type (Figure 1). Differential miRNA proﬁling experiments
comparing different progenitor populations differentiated from
the same neuro-epithelial cells can help identifying miRNAs
speciﬁcally involved in progenitor speciﬁcation. In addition, the
involvement of miRNA in progenitor response to patterning
molecules can easily be assessed in a dose-dependent manner.
IN VITRO MODELING OF THE BALANCE BETWEEN SELF-RENEWAL AND
NEURONAL DIFFERENTIATION
During embryogenesis, progenitors committed to the neural lin-
eage and regionalized undergo several rounds of symmetric divi-
sions (self-renewal) before giving rise to terminally differentiated
FIGURE 1 | Schematic depicting the different strategies used to produce different neuronal sub-types from PSC. Related pathway activations are in
green and inhibitions are in red. SHH, sonic hedgehog; FGF-8, ﬁbroblast growth factors 8; RA, retinoic acid.
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post-mitotic neurons. This active phase of self-renewal is necessary
to constitute thenmaintain a large pool of progenitors. In addition,
for many brain structures, waves of terminal differentiation occur
at different time points allowing the genesis of different sub-types
of neurons from the same starting progenitors (McConnell, 1995).
This is particularly illustrated by the formation of the mammal
neocortex layers. Glutamatergic projection neurons of the neo-
cortex organize as six layers in the human brain. All layers are
formed from the same pool of progenitors located in the corti-
cal sub-ventricular zone. However, early born neurons will form
the deeper layers (V–VI) whereas later born neurons will consti-
tute the upper layers (II–IV; Rakic, 1974; Frantz and McConnell,
1996). Studying the regulationof this balance between self-renewal
and terminal differentiation is therefore particularly meaningful
to improve our ability to grow PSC-derived neural progenitors
in vitro in order to control the production of relevant neuronal
sub-types but also because subtle disturbance of this balance may
be involved in the genesis of many neuro-developmental diseases.
Pluripotent stem cell-derived self-renewing neural progenitors
can be obtained by placing the early neural rosettes, which con-
tain neuro-epithelial cells, in culture media supplemented with
mitogenic factors. When cultivated in presence of Notch ligands
and SHH, early neuro-epithelial cells retain both the morphologi-
cal organization (epithelial structures) and molecular signature of
naïve neuro-epithelial cells (Elkabetz et al., 2008). These rosette-
derived neural stem cells (R-NSC) can be maintained upon several
rounds of symmetric division and produce different sub-types of
neurons after a short exposure to relevant patterning molecules.
Successful ampliﬁcation of neuro-epithelial was also achieved
usingFGF-2 aloneor in combinationwith epidermal growth factor
(Delaloy et al., 2010; Falk et al., 2012) with cells responding at least
in part to patterning molecules. It remains to establish whether
the molecules used to amplify neural progenitors by the mean
of self-renewal are relevant to the physiological situation. How-
ever, upon mitogens withdrawal, these neural progenitors quickly
exit the proliferative compartment to engage the ﬁnal program of
differentiation as post-mitotic neurons. It is therefore possible to
screen formiRNAs involved in themaintenance of the proliferative
state or, in contrast, in the decision of terminal differentiation.
SYNAPTOGENESIS AND FUNCTIONAL NETWORK
To be considered as fully functional, neurons have to form
electrically active synapses and organize as complex neuronal net-
works. Formation of electrically functional synapses has been
recorded in most of PSC-derived neuronal sub-types. Mixed
population of forebrain neurons (which include GABAergic and
glutamatergic neurons) can self-organize as a network forming
functional synapses (Kim et al., 2011b). When the differentia-
tion is directed to form cortical pyramidal neurons, formation
of glutamatergic synapses can be monitored by measuring the
assembly of cellular contact where presynaptic proteins are co-
localized with PSD-95, a protein of the post-synaptic densities
speciﬁc of glutamatergic synapses. Electrophysiology experiments
showedneuronal responses to glutamate challenges. The recording
of spontaneous action potentials indicated that these pyramidal
neurons organized as complex autonomous networks (Shi et al.,
2012). Telencephalic GABAergic interneurons, with a striatal or a
cortical identity, also form spontaneously vesicular GABA trans-
porter (VGAT)/gephyrin-expressing GABAergic synapses that are
electrically active (Carri et al., 2013; Maroof et al., 2013). PSC-
derived mesencephalic neurons efﬁciently release dopamine and
exhibit spontaneous, network-mediated, electrical activity (Kriks
et al., 2011). Finally, several studies reported that PSC-derived
spinal cord motor neurons are able to form functional neuro-
muscular junctions when co-cultivated with myotubes (Umbach
et al., 2012). In all these culture systems, synapse formation and
activity can easily be monitored both morphologically, follow-
ing clustering and co-expression of speciﬁc molecular markers,
and functionally, measuring calcium entry in response to phar-
macological stimulations or by the mean of electrophysiological
recordings. This opens the path to functional studies of miRNA
involvement in the very early steps of synaptogenesis as well as in
modulating synaptic activity.
PLURIPOTENT STEM CELLS TO STUDY miRNA FUNCTION IN
PHYSIOLOGICAL NEUROGENESIS
So far, hPSC and their neural progeny have contributed to increase
our knowledge regarding the involvement of miRNAs in two neu-
rogenesis steps that are hardly accessible in vivo: the very early stage
of engagement into the neural lineage and the governance of self-
renewal/migration/neuronal differentiation of neural progenitors
(Figure 2).
miRNA REGULATING THE COMMITMENT INTO THE NEURAL
At least two miRNAs have been demonstrated to promote the con-
version of PSCs into neuro-epithelial cells, miR-125 and miR-145.
Xu et al. (2009) used the EBs model to identify miRNAs regulat-
ing hESC differentiation. Using a whole genome approach based
on Taqman qPCR, they showed that miR-145 expression quickly
increased as hESC enter the differentiation process. Forced expres-
sion of miR-145 favored the differentiation along the ectodermal
lineage including the neural fate. In contrast, when miR-145
activity was blocked using locked nucleic acid (LNA)-antimiR
oligos, endodermal differentiation occurred. The authors iden-
tiﬁed Oct-4 and KLF-4 as relevant targets of miR-145. miR-125
was also reported as a key regulator of hESC neural conversion.
We induced the neural conversion of hESCs by treating them
with the two Smad inhibitors: Noggin and SB431542 (Boissart
et al., 2012). Using this model, the kinetics of activation of three
brain-expressedmiRNAs,miR-9,miR-124, andmiR-125, was ana-
lyzed over time. Only miR-125 was found to be activated in a
time window compatible with a role in the neural commitment
decision. Functional studies conﬁrmed that miR-125 activity was
necessary to fully achieve an efﬁcient engagement of hESC into
the neural lineage by both promoting hESC differentiation and
blocking alternative, non-neural fate choices. Silencing by miR-
125 of Smad-4, the key co-factor of activin- and BMP-dependent
Smad pathways, was central to its role in the promotion on neural
commitment.
Next tomiRNAs actively promoting neural conversion aremiR-
NAs that block this critical decision in order to maintain the cells
in a pluripotent state or foster alternative fates. miRNAs of the
miR-302/miR-367 family are particularly enriched in PSC. miR-
302/miR-367 target several endogenous inhibitors of BMP and
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FIGURE 2 | Schematic depicting the different steps of neurogenesis
recapitulated in vitro using hPSC and the miRNA demonstrated as
regulators of these steps.
activin pathways including Lefty, TOB2, DAZAP2, and SLAIN1.
Consequently, Smad activity is elevated in cells expressing these
miRNAs which render neural conversion impossible (Lipchina
et al., 2011). More recently, miR-302 was shown to directly target
NR2F2, a transcription factor involved in the very early trigger-
ing of the neural genetic program, suggesting that miR-302 may
more speciﬁcally avoid a spontaneous commitment of PSCs into
the neural lineage (Rosa and Brivanlou, 2011). Next to miR-302
family members, the miR-371/miR-372/miR-373 cluster is also
considered as a potent inhibitor of the neural lineage commit-
ment (Kim et al., 2011a). Expression of miR-371 is induced by
the pluripotency-associated transcription factor KLF-4. PSC lines
exhibiting high levels of endogenous miR-371 showed an altered
neurogenic potential. Efﬁcient neural conversion was restored
upon miR-371 inhibition using LNA-antagomiR oligos demon-
strating a causal role of miR-371 in repressing the neural fate.
Interestingly, miR-371 activity did not compromise differentia-
tion into other lineages but seemed rather speciﬁc of the neural
lineage as it controlled the sensitivity of the PSC response to BMPs
signal.
Taken together, the identiﬁcation of miRNAs regulating the
efﬁciency of PSCs neural conversion has highlighted the impor-
tance of the ﬁne tuning of Smad-dependent pathways. miR-125,
miR-302, and miR-371 both target proteins involved directly
in signaling mediated by receptors of the TGF-beta family and
modulate ﬁnely the strength of the signal transduction. miRNAs
promoting the neural conversion target directly the Smad proteins
whereas miRNAs favoring alternative fates contribute to secure
the activation of these pathways by targeting their endogenous
inhibitors. The hPSC model of neural differentiation has there-
fore contributed to illustrate how subtle the decision of lineage
commitment is regulated.
miRNA REGULATING PROLIFERATION AND DIFFERENTIATION OF
NEURAL PROGENITORS
A crucial role of miRNAs in regulating the pool of neural progen-
itors has been well established in rodent models (Volvert et al.,
2012). The brain-enriched miR-9 is mainly expressed in neu-
rogenic areas during development suggesting its involvement in
molecular mechanisms regulating self-renewal and proliferation
of neural progenitors (Deo et al., 2006). Accordingly, miR-9 has
been found highly expressed in self-renewing progenitors stably
established from the multipotent and immature hESC-derived
neuro-epithelial cells (Delaloy et al., 2010; Boissart et al., 2012).
In hESC-derived progenitors ampliﬁed as neurospheres using
FGF-2, miR-9 plays a crucial role in the maintenance of the capac-
ity of proliferation and migration of these progenitors (Delaloy
et al., 2010). Interestingly, the authors also assessed the role of
miR-9 in the transition between immature multipotent neuro-
epithelial cells and the fate restricted mature neural progenitors.
They showed that miR-9 activity was essential to this maturation
step by directly targeting the cytosolic protein Stathmin.
In contrast to the proliferation-promoting action of miR-9,
several miRNAs have been identiﬁed as regulators of the deci-
sion of terminal neuronal differentiation. The neuronal-speciﬁc
miR-124 was found enriched in culture of hPSC-derived post-
mitotic neurons but not in the proliferative neural progenitors
from which they were differentiated (Delaloy et al., 2010; Stappert
et al., 2013). Functional studies showed that its forced expression
increased the rate of neuronal differentiation whereas blocking its
activity resulted in an impaired neuronal production (Stappert
et al., 2013).
Next to the study of miRNAs already described as brain-
speciﬁc, a differential, whole genome, miRNAs proﬁling was
performed comparing self-renewing hESC-derived multipotent
neuro-epithelial stem cells (lt-NES) to their neuronal progeny
(Stappert et al., 2013). This extensive proﬁling pointed to
additional miRNAs enriched in differentiated neurons, miR-
125b, miR-153, miR-181a/181a*, and the cluster miR-324-
5p/3p. Ectopic expression of miR-153, miR-181a/181a*, and
miR-324-5p/3p shifted lt-NES cells from self-renewal to neuronal
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differentiation. lt-NES represent ventral hindbrain precursors that
mainly give rise of GABAergic interneurons. However, they can
also produce small amount of tyrosine hydroxylase (TH) neu-
rons, an enzyme converting L-tyrosine into L-DOPA, considered a
marker of catecholaminergic neurons. The authors asked whether,
next to promoting neuronal differentiation, these miRNA can
also inﬂuence the neuronal fate. miR-125b and miR-181a both
increased the number of TH positive neurons. In contrast, miR-
181a* inhibited the formation of TH neurons and promoted the
production of GABAergic neuronal cells.
These pioneer studies illustrate how hPSC can greatly improve
our knowledge about miRNAs involvement in physiological neu-
rogenesis by helping elucidating the functional impact of miRNA
activities and identifying their targets.
DECIPHERING THE IMPACT OF miRNAs IN
NEURO-DEVELOPMENTAL DISEASES USING
PATIENT-DERIVED iPSCs
THE iPSC BREAKTHROUGH
In 2007, Yamanaka and colleagues made the breakthrough dis-
covery of a simple method to reprogram human somatic adult
cells into fully PSCs, a type of cells now widely known as iPSCs
(Takahashi et al., 2007). Since iPSC can be derived from virtually
all nucleated cell types of the body, it suddenly removed the barri-
ers raised until this date by the use of PSC derived from embryos
that limited investigations to cells with unknown clinical status
(the so-called wild-type cells) or to lines carrying mutations of
the few diseases eligible for a pre-implantation genetic diagnosis
(PGD). PSC induced from somatic cells offer the unlimited pos-
sibility to model neurogenesis from any patient including those
for which the cause of the disease is not fully identiﬁed – e.g.,
multifactorial disorders – but with a well-documented clinical
characterization (Bellin et al., 2012).
Although promising, the ﬁeld of iPSC is still considered “at
work” and questions remain regarding the accuracy of mod-
eling disease with a strong epigenetic origin using genetically
reprogramed cells. Indeed, concerns have been raised about
the differences in genes expression, including miRNA proﬁles,
between iPSC and hESC, suggesting that, next to the disease
context, iPSC behavior may also be inﬂuenced by the technique
and efﬁciency of reprograming as well as by the cell type from
which the iPSC line was produced (Chin et al., 2009; Marchetto
et al., 2009; Vitale et al., 2012). Consequently, iPSC may model
neuro-developmental diseases with strong epigenetic components
differently than hESC (Urbach et al., 2010). However, some evi-
dences indicate that certain epigenetic marks are conserved with
reprograming, including parental imprinting (Chamberlain et al.,
2010; Yang et al., 2010). To date, several iPSC lines have been
derived from patients with various neuro-developmental disor-
ders including Rett’s syndrome (RS; Kim et al., 2011c), fragile X
syndrome (FXS; Urbach et al., 2010), Down’s syndrome (Briggs
et al., 2013; Weick et al., 2013), Timothy’s syndrome (Pasca et al.,
2011), Angelman’s syndrome (Chamberlain et al., 2010), Prader–
Willi’s syndrome (Yang et al., 2010), and Schizophrenia (Brennand
et al., 2011). Some of those have been shown to recapitulate in vitro
important features of the diseases which make them attractive
tools to further study mechanisms leading to pathological phe-
notypes including the inﬂuence of miRNAs already described as
dysregulated in brains of patients or in animal models (Table 1).
MONOGENIC SYNDROMES OF AUTISM SPECTRUM DISORDERS AND
MENTAL RETARDATION
Micro-RNAs, as ﬁne regulators of protein translation, inﬂuence
directly the level of gene expression. A central role of synaptic
gene dosage in the emergence of ASDs and mental retardation
(MR) is now well established (Toro et al., 2010), suggesting that
miRNAs studies in iPSC models may bring some light into the
dark areas of these early onset neuro-developmental disorders.
More particularly, understanding the link between genes respon-
sible for monogenic forms of ASD/MR and the miRNA machinery
may help understand why patients with the same genetic mutation
in coding sequences can develop differentially severe symptoms.
So far, iPSC have been successfully derived from individuals with
two monogenic forms of ASD/MR: the RS and the FXS. RS is
Table 1 | Summary of iPSC lines in which the role of miRNAs dysregulated in animal models or human brains can be further investigated.
Disease Origin References of iPSC lines Phenotype of iPSC-derived
neurons
miRNAs of interest
Fragile X syndrome Loss of function of
FMRP (FMR1 gene)
Urbach et al. (2010),
Sheridan et al. (2011)
Hyper-excitability of glutamatergic
synapses
DICER and AGO-1 complexes
Rett’s syndrome Loss of function of
MeCP2 transcriptional
repressor
Marchetto et al. (2010),
Kim et al. (2011c),
Cheung et al. (2012)
Decreased soma size, neurite
atrophy, decreased efﬁciency of
glutamatergic synapses
miR-132, miR-184, miR-483-5p,
miR-212
Schizophrenia Multifactorial Urbach et al. (2010);
Brennand et al. (2011),
Paulsen Bda et al. (2012),
Robicsek et al. (2013)
Diminished neuronal connectivity miR-17-5p, miR-34a, miR-107,
miR-122, miR-132, miR-134,
miR-137
Down’s syndrome Additional copy of
chromosome 21
Briggs et al. (2013),
Weick et al. (2013)
Reduced synaptic activity, increased
sensitivity to oxidative stress
miR-99a, miR-125b, miR-155,
miR-802, Ret 7c
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an inherited neuro-developmental disorder with an X-linked gene
inheritancemainly affectingwomen. Most forms of RS are due to a
loss of function mutation in the transcriptional repressor MeCP2
(methyl CpG binding protein 2; Ravn et al., 2011). RS iPSC repli-
cate some prototypical features found in animal models including
decreased neuronal soma size, neuritic atrophy and decreased efﬁ-
ciency of glutamatergic synapses (Marchetto et al., 2010; Kim et al.,
2011c; Cheung et al., 2012). Disruption of MeCP2 gene in mice
leads to the dysregulation of a set of miRNA potentially of inﬂu-
ence in neurogenesis including miR-132, miR-184, miR-483-5p,
and miR-212 (Nomura et al., 2008; Im et al., 2010; Urdinguio
et al., 2010; Han et al., 2013). The role of each miRNA in the
development of typical RS neuronal features can be addressed
using iPSC-derived neurons. Similarly, several iPSC lines have
been derived from individuals with the FXS. In FXS, abnormal
expansion of a CGG triplet in the 5′UTR of the FMR1 gene leads
to the defective translation of the FMR1 gene and to the loss of
the resulting protein fragile X mental retardation protein (FMRP;
Wijetunge et al., 2013). FXS iPSC lines-derived neurons recapit-
ulate the typical hyper-excitability of glutamatergic synapses and
developmental defects described in animal models (Urbach et al.,
2010; Sheridan et al., 2011). FMRP has been shown to directly
control miRNA biogenesis through direct interaction with DICER
and AGO-1 complexes (Jin et al., 2004). Of interest, functional
investigations of miRNAs regulated by MeCP2 or FMRP proteins
in iPSC-derived neurogenesis models may help address whether
the dysregulation of these miRNAs have a real impact on the
strength of the pathologic phenotypes and whether this can be
reversed.
MULTIFACTORIAL SYNDROMES
One of the main interests of recapitulating neurogenesis with
patient-derived iPSC is the opportunity to address the role of
miRNAs in a human genetic background permissive to the devel-
opment of multifactorial diseases such as schizophrenia or Down’s
syndrome. Although psychiatric disorders, such as schizophrenia,
affect several brain regions and produce a complex array of clin-
ical symptoms, basic phenotypes likely exist at the level of single
neurons and simple networks. Being highly heritable, it is hypoth-
esized that these disorders are amenable to cell-based studies
in vitro (Brennand et al., 2012). Accordingly, the human-induced
PSC (hiPSC) technology makes it possible to study schizophrenia
and other psychiatric disorders using live human neurons with
a genetic predisposition without knowledge of the genes inter-
acting to produce the disease state. Genome-wide proﬁling has
listed a number of changes in miRNAs expression levels in the
brain of patients with a diagnosis of schizophrenia (Kim et al.,
2010; Moreau et al., 2011; Santarelli et al., 2011). These include
miR-17-5p, miR-34a, miR-107, miR-122, the brain-speciﬁc miR-
132, the synaptic miR-134, miR-185, miR-382, and miR-652.
Interestingly, a single-nucleotide polymorphism in miR-137, a
miRNA previously reported as a regulator of neuronal matura-
tion, was consistently found to be one of the common alleles
associated with a high risk of developing schizophrenia (Whal-
ley et al., 2012). To date, several groups have obtained iPSC
from individuals diagnosed with schizophrenia (Urbach et al.,
2010; Brennand et al., 2011; Paulsen Bda et al., 2012; Robicsek
et al., 2013) and have described impaired neurogenesis in these
lines opening the path to further investigations regarding miRNA
active participation to the initiation and the progression of the
disease.
Another multifactorial disease for which hiPSC would be a
valuable study tool is Down’s syndrome, also known as trisomy 21.
In the human, Down’s syndrome sums MR, craniofacial morpho-
logical abnormalities and heart failure due to an additional copy of
the long arm of chromosome 21 (Hsa21). Hsa21 contains approx-
imately 552 genes, 166 of which are orthologous to genes localized
in syntenic regions of three mouse chromosomes: Mmu16 (110
orthologous genes), Mmu17 (19 orthologous genes), and Mmu10
(37orthologous genes; Rueda et al., 2012). Basedon these homolo-
gies, several mouse models that are trisomic for different sets of
Hsa21 genes have been developed but failed to properly recapit-
ulate the complete neurological symptoms of Down’s syndrome,
suggesting that Hsa21 might contain additional elements that are
human-speciﬁc. Hsa21 has been predicted to contain at least ﬁve
nc-RNAs, miR-99a, miR-125b, miR-155, miR-802, and Ret-7c
(Kuhn et al., 2008). The recently published trisomic iPSC lines
(Briggs et al., 2013; Weick et al., 2013) will probably help address-
ing the question of the importance of gene dosage, including
miRNA, in the development of the neurological features of Down’s
syndrome.
CONCLUSION
By their ability to recapitulate human neurogenesis in vitro
and their ﬂexibility regarding genetic manipulation, hPSC have
revealed valuable tools to help deciphering the role of miRNAs in
the earlier events of human neurogenesis.
So far, hESC remain the“gold standard” to faithfully investigate
the functional consequences of miRNA activity on different steps
of human neurogenesis since they still represent the closest cellu-
lar model to the physiological situation. However, the iPSC have
revolutionized the ﬁeld of PSCs used as models of neurogenesis
in two ways. Firstly, their somatic origin and the relative simplic-
ity of the reprograming process has dramatically expanded the
use of PSCs in general by removing the ethical constraint linked to
embryo destruction. Secondly, iPSC derived from individuals with
a known clinical proﬁle represent real “patients in a dish”and offer
for the ﬁrst time the opportunity to address the role of miRNAs
in the etiology of complex neuro-developmental disorders using
patient-derived neurons. Many questions regarding the iPSC sys-
tem remain to be answered and more particularly whether the
reprograming step can actually compromise the proper modeling
of a disease by erasing epigenetic signatures including the genuine
miRNA expression proﬁle.
While still in its infancy, the hPSC ﬁeld has already demon-
strated its usefulness to elucidate the function of miRNA in critical
aspect of human neurogenesis. It should reveal its full potential
in the coming years to become a standard that will complement
studies performed in animal models.
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